Document:

ex-10.4

  Exhibit 10.4
  
 EXCLUSIVE LICENSE and SALES AND LICENSING AGREEMENTS FIRST
 AMENDMENT
  
 THIS FIRST AMENDEMENT (the “First Amendment”) is made and entered into as of the 25th day of June 2020 (the “Effective Date”). by and between Rapid Therapeutic Science Laboratories, Inc., a Nevada for profit company, on behalf of its assignor, Texas MDI, Inc. a Texas for-profit corporation (the “Manufacturer”) and EM3 Methodologies, LLC, an Arizona limited liability company, and Richard Adams, individually a resident of Arizona, (collectively the “Company”). Company and Manufacturer may be collectively referred to herein as the “Parties,” and individually as a “Party.”
  
 RECITALS:
  
 WHEREAS, Company and Manufacturer previously executed an Exclusive License Agreement on October 1, 2019 and both parties are satisfactorily performing under that Agreement;
  
 WHEREAS, Company and Manufacturer’s predecessor and its assignee previously executed a Sales and Licensing Agreement on November 21, 2018 and both patties are satisfactorily performing under that Agreement;
  
 WHEREAS, both Parties recognize that the Company has rights to its intellectual property known as the Desirick Procedure, and will continue to maintain those rights as they originally existed: and
  
 WHEREAS, the Company and Manufacturer wish to amend both respective agreements through this First Amendment.
  
 NOW, THEREFORE, for and in consideration of the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:
  
 1.Agreements: 
  
 1.1.Richard Adams is from time to time providing assistance to the Manufacturer or its designee regarding Manufacturer’s activities using the Desirick Procedure. 
  
 1.2.Richard Adams agrees he is being compensated for such assistance separate from the two (2) prior agreements recited herein. 
  
 1.3.Manufacturer’s Improvements shall mean any addition, alteration, change, development, enhancement or modification to the EM3 Technology or its deployed process such as mechanical or chemical changes or manipulations made by or on behalf of Manufacturer. 
  
 1.4.As such, any Manufacturer’s Improvements to the Desirick Procedure, whether chemical or mechanical, that originate at the direction or in the presents of Manufacturer or its employees, owners, etc..., shall be the sole and exclusive property of Manufacturer, unless acknowledged to the contrary by Manufacturer in writing. 
  
 1.5.Richard Adams agrees to assist in the protection of such improvements to the extent necessary to protect Manufacturer’s legal rights. 
 
  
 
 1.6.Richard Adams agrees to maintain strict confidentiality of any such improvement. 
  
 1.7.The intent of the First Amendment is to protect Manufacturer’s development of Trade Secrets under both Texas and Arizona law to the economic benefit of Manufacturer or its designees. 
  
 1.8.Richard Adams expressly agrees that Manufacturer has made Manufacturers’ Improvements to the Desirick Procedure and its formulation prior to the execution of this First Amendment and that this First Amendment applies retroactively to such Manufacturers’ Improvements. 
  
 2.Consideration: 
  
 2.1The Consideration for this First Amendment is the payment to Richard Adams of 100,000 shares of the common restricted stock of Rapid Therapeutic Science Laboratories, Inc. (“RTSL”). 
  
  
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.
  
  
 	 COMPANY:
	 Manufacturer

	  
	  

	 EM3 Methodologies, LLC
	 RTSL on behalf of Texas MDI, Inc.

	  
	  

	  
	  

	 /s/ Richard Adams
	 /s/ Donal R. Schmidt, Jr.

	 By: Richard Adams, Managing Member
 and Individually
	 By: Donal R. Schmidt, Jr., CEOEX-4.1

 EXHIBIT 4.1 

SPECIMEN UNIT CERTIFICATE 

NUMBER UNITS 
 U- 

Equity Distribution Acquisition Corp. 

SEE REVERSE FOR CERTAIN DEFINITIONS 

CUSIP      

UNITS CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE-THIRD OF ONE REDEEMABLE WARRANT TO PURCHASE
ONE SHARE OF CLASS A COMMON STOCK 
 THIS CERTIFIES THAT 

is the owner of                 Units. 

Each Unit (“Unit”) consists of one (1) share of Class A common stock, par value $0.0001 per share (“Common Stock”), of Equity
Distribution Acquisition Corp., a Delaware corporation (the “Company”), and one-third (1/3) of one redeemable warrant (each whole warrant, a “Warrant”). Each whole Warrant entitles the
holder to purchase one (1) share (subject to adjustment) of Common Stock for $11.50 per share (subject to adjustment). Each Warrant will become exercisable on the later of (i) thirty (30) days after the Company’s completion of a
merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (each a “Business Combination”), and (ii) twelve (12) months from the closing of the
Company’s initial public offering, and will expire unless exercised before 5:00 p.m., New York City time, on the date that is five (5) years after the date on which the Company completes its initial Business Combination, or earlier upon
redemption or liquidation (the “Expiration Date”). The Common Stock and Warrants comprising the Units represented by this certificate are not transferable separately prior to    , 2020, unless Credit Suisse Securities
(USA) LLC elects to allow earlier separate trading, subject to the Company’s filing with the Securities and Exchange Commission of a Current Report on Form 8-K containing an audited balance sheet
reflecting the Company’s receipt of the gross proceeds of the initial public offering and issuing a press release announcing when separate trading will begin. No fractional warrants will be issued upon separation of the Units and only whole
Warrants will trade. The terms of the Warrants are governed by a Warrant Agreement, dated as of     , 2020, between the Company and Continental Stock Transfer & Trust Company, as Warrant Agent, and are subject to the
terms and provisions contained therein, all of which terms and provisions the holder of this certificate consents to by acceptance hereof. Copies of the Warrant Agreement are on file at the office of the Warrant Agent at 1 State Street, 30th Floor,
New York, New York 10004, and are available to any Warrant holder on written request and without cost. 

 This certificate is not valid unless countersigned by the Transfer Agent and Registrar of the
Company. 
 This certificate shall be governed by and construed in accordance with the internal laws of the State of New York. 

Witness the facsimile signatures of its duly authorized officers. 
  

			
		
	By:	 	 

            

		 	Chief Financial Officer

 Equity Distribution Acquisition Corp. 

The Company will furnish without charge to each unitholder who so requests, a statement of the powers, designations, preferences and relative,
participating, optional or other special rights of each class of stock or series thereof of the Company and the qualifications, limitations, or restrictions of such preferences and/or rights. 

The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out
in full according to applicable laws or regulations: 
  

															
	 TEN COM
	  	—	  	 as tenants in common
	  	 UNIF GIFT MIN ACT
	  	—	  		  	Custodian	  	
		  		  		  		  		  	  
	  		  	  

	 	  	 	  	 	  	 	  	 	  	(Cust)	  	 	  	(Minor)
	 TEN ENT
	  	—	  	 as tenants by the

entireties
	  		  		  	 under Uniform Gifts to

Minors Act

		  		  		  		  		  	
	 	  	 	  	 	  	 	  	 	  	(State)
	 JT TEN
	  	—	  	 as joint tenants with

right of survivorship and

not as tenants in

common
	  		  		  	

 Additional abbreviations may also be used though not in the above list. 

 For value received, hereby sells, assigns and transfers unto 

PLEASE INSERT SOCIAL SECURITY OR 

OTHER IDENTIFYING NUMBER OF 

ASSIGNEE 

(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) 

Units represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said Units on the books of the within
named Company with full power of substitution in the premises. 
  

			
	Dated _______________________	 	
		 	 
		 	 Notice: The signature to this assignment

must correspond with the name as written
 upon the face of the
certificate in every
 particular, without alteration or enlargement

or any change whatever.

	Signature(s) Guaranteed:	 	
	 	 	
	 THE SIGNATURE(S) MUST BE
 GUARANTEED BY AN
ELIGIBLE
 GUARANTOR INSTITUTION (BANKS,
 STOCKBROKERS, SAVINGS
AND LOAN
 ASSOCIATIONS AND CREDIT UNIONS
 WITH MEMBERSHIP IN AN
APPROVED
 SIGNATURE GUARANTEE MEDALLION
 PROGRAM, PURSUANT TO
S.E.C. RULE
 17Ad-15 OR ANY SUCCESSOR RULES).
	 	

 In each case, as more fully described in the Company’s final prospectus dated     , 2020, the
holder(s) of this certificate shall be entitled to receive a pro-rata portion of certain funds held in the trust account established in connection with the Company’s initial public offering only in the
event that (i) the Company redeems the shares of Common Stock sold in its initial public offering and liquidates because it does not consummate an initial business combination by the date set forth in the Company’s amended and restated
certificate of incorporation, (ii) the Company redeems the shares of Common Stock sold in its initial public offering in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation
(a) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s initial business combination or to redeem 100% of the Common Stock if it does not consummate an initial business
combination by the date set forth in the Company’s amended and restated certificate of incorporation or (b) with respect to any other provisions relating to the rights 

 
of holders of the Common Stock or pre-initial Business Combination activity or (iii) if the holder(s) seek(s) to redeem for cash his, her or its
respective shares of Common Stock in connection with a tender offer (or proxy solicitation, solely in the event the Company seeks stockholder approval of the proposed initial business combination) setting forth the details of a proposed initial
business combination. In no other circumstances shall the holder(s) have any right or interest of any kind in or to the trust account.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]